Search | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes

    ... chronic anemia and red blood cell (RBC) transfusion dependence impact negatively on survival and quality of life (QoL), ... have been shown to be effective in achieving transfusion independence by altering the natural course of MDS. ...

    Research Article last updated 07/20/2018 - 5:14pm.

  2. The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: A clinical practice guideline.

    ... the aging population. Treatment includes red blood cell transfusion for anemia . The immunomodulatory agents (imids) ... and lenalidomide may induce transfusion independence . This guideline systematically reviews evidence on imids to ...

    Research Article last updated 07/20/2018 - 5:14pm.

  3. Long-term follow-up of patients with moderate aplastic anemia and pure red cell aplasia treated with daclizumab.

    ... achieved long-term packed red blood cell PRBC transfusion independence , and all PRCA responders achieved long-term transfusion PRBC ...

    Research Article last updated 07/20/2018 - 5:14pm.

  4. Front-line immunosuppressive treatment of acquired aplastic anemia

    ... 60 and 80%. CsA should be given for 12 months until transfusion independence is achieved and then tapered very slowly in the presence of a ...

    Research Article last updated 07/20/2018 - 5:14pm.

  5. Durable long-term responses in patients with myelodysplastic syndromes treated with lenalidomide.

    ... has proven efficacy and safety and has been shown to reduce transfusion requirements and reverse cytogenetic abnormalities in lower-risk ... To date, all patients maintained long-term transfusion independence (over 4.5 years) while receiving oral lenalidomide therapy, ...

    Research Article last updated 07/20/2018 - 5:14pm.

  6. Lenalidomide for del(5q) and Non-del(5q) Myelodysplastic Syndromes

    ... Lenalidomide leads to high rates of erythroid transfusion independence in low and intermediate-1 risk International Prognostic ...

    Research Article last updated 07/20/2018 - 5:14pm.

  7. Lenalidomide performance in the real world: Patterns of use and effectiveness in a Medicare population with myelodysplastic syndromes.

    ... is approved for the treatment of anemia with transfusion dependence (TD) in patients with lower-risk myelodysplastic ... transfusion user (TU), 1 transfusion; and transfusion independence (TI), no transfusions. RESULTS: A total of 753 of ...

    Research Article last updated 07/20/2018 - 5:15pm.

  8. Predictors of Hemoglobin Response to Eculizumab Therapy in Paroxysmal Nocturnal Hemoglobinuria

    ... to response criteria. Complete response was defined as transfusion independence with normal hemoglobin for age/sex, absence of ...

    Research Article last updated 07/20/2018 - 5:14pm.

  9. An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes

    ... rate with an additional 49% stable disease, 34% transfusion independence ) included 1 complete response lasting >1 year. No responses ...

    Research Article last updated 07/20/2018 - 5:15pm.

  10. Patients with Myelodysplastic Syndromes Treated with Azacitidine in Clinical Practice: The AVIDA® Registry

    ... treatment decisions. Hematologic improvement (HI) and transfusion independence (TI) assessments used IWG-2000 criteria. Enrolled were 421 ...

    Research Article last updated 07/20/2018 - 5:15pm.